Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

Ads

You May Also Like

ALRT Introduces Value Pricing for Diabetes Management

RICHMOND, Va., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Medical practices, health insurers, self-insured employers, ...

Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), ...